CYTK Cytokinetics Inc

Price (delayed)

$72.17

Market cap

$8.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.84

Enterprise value

$10.14B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 21

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
The revenue has increased by 20% since the previous quarter
Cytokinetics's gross profit has increased by 17% from the previous quarter
Cytokinetics's gross margin has increased by 6% YoY but it has decreased by 2.4% from the previous quarter
The debt has soared by 63% YoY
The net income is down by 35% year-on-year and by 6% since the previous quarter

Key stats

What are the main financial stats of CYTK

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
2.06%
1 week
-6.04%
1 month
9.27%
1 year
122.68%
YTD
13.58%
QTD
9.5%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$105.82M
Gross profit
$103.26M
Operating income
-$640.25M
Net income
-$829.61M
Gross margin
97.6%
Net margin
-784%
Cytokinetics's operating margin has soared by 79% YoY and by 13% from the previous quarter
The net margin has soared by 76% YoY and by 12% from the previous quarter
The net income is down by 35% year-on-year and by 6% since the previous quarter
The revenue has increased by 20% since the previous quarter

Price vs fundamentals

How does CYTK's price correlate with its fundamentals

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
84.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
95.82
The EPS has contracted by 29% YoY and by 4.6% from the previous quarter
CYTK's equity is down by 25% since the previous quarter
CYTK's P/S is 81% below its 5-year quarterly average of 433.7 but 16% above its last 4 quarters average of 71.3
The revenue has increased by 20% since the previous quarter

Efficiency

How efficient is Cytokinetics business performance
The ROS has soared by 75% YoY and by 12% from the previous quarter
The company's return on assets fell by 42% YoY and by 5% QoQ
CYTK's return on invested capital is down by 21% year-on-year

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 39% smaller than the total liabilities
Cytokinetics's total liabilities has increased by 37% YoY
Cytokinetics's quick ratio has decreased by 30% YoY and by 7% from the previous quarter
The debt has soared by 63% YoY
Cytokinetics's debt to equity has increased by 47% YoY and by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.